Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.

ABSTRACT:

Importance

Apathy is a frequent neuropsychiatric symptom in dementia of Alzheimer type and negatively affects the disease course and patients' and caregivers' quality of life. Effective treatment options are needed.

Objective

To examine the efficacy and safety of the dopamine and noradrenaline reuptake inhibitor bupropion in the treatment of apathy in patients with dementia of Alzheimer type.

Design, setting, and participants

This 12-week, multicenter, double-blind, placebo-controlled, randomized clinical trial was conducted in a psychiatric and neurological outpatient setting between July 2010 and July 2014 in Germany. Patients with mild-to-moderate dementia of Alzheimer type and clinically relevant apathy were included. Patients with additional clinically relevant d

SUBMITTER: Maier F 

PROVIDER: S-EPMC7256670 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature